Amphastar Pharmaceuticals Receives 'Hold' Rating from Analysts

Analysts cite mixed outlook for the specialty drug maker's stock performance

Apr. 8, 2026 at 10:25am

Got story updates? Submit your updates here. ›

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has received an average 'Hold' rating from eight investment firms currently covering the stock, according to a MarketBeat report. While two analysts have assigned a 'Buy' rating, six others have rated the stock as 'Hold', with a 12-month average price target of $29.50.

Why it matters

Amphastar's mixed analyst ratings reflect the challenges facing the specialty pharmaceutical industry, including pricing pressures and competition from generic drugs. The company's performance will be closely watched by investors seeking insight into the broader trends impacting drug manufacturers.

The details

The analysts' ratings for Amphastar Pharmaceuticals are based on the company's financial results, product pipeline, and competitive positioning. While some see growth potential in Amphastar's injectable generic drugs, others are more cautious about the company's ability to maintain market share and profitability.

  • Amphastar Pharmaceuticals' stock price has ranged from a 12-month low of $17.03 to a high of $31.26.

The players

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California that focuses on the development, manufacturing and commercialization of injectable and inhalation products.

Weiss Ratings

A financial research firm that recently reiterated a 'hold (c-)' rating on Amphastar Pharmaceuticals' stock.

Wells Fargo & Company

An investment bank that reduced its target price for Amphastar Pharmaceuticals from $34 to $30 and maintained an 'overweight' rating.

Barclays

An investment bank that initiated coverage of Amphastar Pharmaceuticals with an 'equal weight' rating and a $30 target price.

Needham & Company LLC

An investment bank that reduced its target price for Amphastar Pharmaceuticals from $34 to $30 while maintaining a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

Amphastar Pharmaceuticals' mixed analyst ratings reflect the challenges facing the specialty pharmaceutical industry, including pricing pressures and competition from generic drugs. While the company's injectable generic drug portfolio offers growth potential, investors will be closely watching Amphastar's ability to maintain market share and profitability in the face of these industry headwinds.